Cambridge Biotech Co-Founded by Alnylam Founder Files for U.S. IPO
A Cambridge-based biotech co-founded by Alnylam Pharmaceuticals’ founder Akshay Vaishnaw filed for a U.S. IPO on September 25, 2026. Focused on RNA therapeutics with multiple Phase II assets and no revenue, the company’s S-1 is expected within weeks. Funding amount and underwriters remain undisclosed.
51CFO view：For biotech IPOs, the CFO must master ASC 730 R&D expense disclosure and ASC 985 software development capitalization—especially when explaining FDA engagement timelines to SEC reviewers. Chinese biotechs targeting Nasdaq need CFOs who’ve directly prepared financial sections for FDA meetings, not just outsourced the work.
A Cambridge-based biotech co-founded by Alnylam Pharmaceuticals’ founder Akshay Vaishnaw filed for a U.S. IPO on September 25, 2026. Focused on RNA therapeutics with multiple Phase II assets and no revenue, the company’s S-1 is expected within weeks. Funding amount and underwriters remain undisclosed.
Source：Google News · 美股 IPO
Why this matters to your CFO search
Where this touches your finance hire
Every listing event changes what you need from a CFO. Start from the step you are actually at.
What kind of CFO does a US IPO need?
S-1 / F-1 filing, US GAAP conversion, roadshow — the hard requirements.
Read →
What to do 18 months before filing
Financial readiness: audit basis, internal control, equity restatement.
Read →
Who runs finance through a SPAC merger?
De-SPAC files F-1 / 424(b); merger audit and disclosure cadence differ.
Read →